Roivant Sciences Ltd. → Arbutus Biopharma Corp ABUS

Item 4 is hereby amended by adding the following to the end thereof: On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the "Offer"), which included the option for shareholders to make a proportionate tender. Roivant made a proportionate tender of its Common Shares in the Offer in order to maintain its proportionate ownership of the Common Shares following completion of the Offer. The Offer expired at 5:00 p.m., New York City time, on September 29, 2026. On October 1, 2026, the Issuer announced that it had taken up and accepted for purchase 46,000,000 Common Shares at a purchase price of US$5.00 per Common Share, including 8,967,383 Common Shares tendered by Roivant pursuant to its proportionate tender, for aggregate consideration to Roivant of approximately US$44,836,915. Following completion of the Offer, Roivant continues to beneficially own approximately 19.5% of the outstanding Common Shares.